FDA Approves Pfizer’s RSV Vaccine ABRYSVO for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF)…
Read More...
Read More...